Novadiscovery
Novadiscovery is an in silico IP factory geared towards superior R&D economics in high unmet need areas.
- Stage Product In Development
- Industry Biotechnology
- Location Lyon, RA, France
- Currency EUR
- Founded April 2010
- Employees 12
- Website novadiscovery.com
Company Summary
Novadiscovery ambitions to become the global leader in predictive modeling solutions applied to drug R&D. Our technology drives the development of efficient and targeted therapies for high unmet need patients in selected therapeutic areas (cancer, cardiovascular, infectious diseases & immunology). The company is structured as an IP factory which gets monetized through an asset-centric funding model and licensing agreements with big pharmas.
Team
-
François-Henri BoisselChief Executive Officer
MBA graduate from ESSEC Business School, François-Henri has spent 4 years with the investment bank Lehman Brothers in London and Tokyo specializing in asset-backed financing.
He has developed an expertise in financial engineering, deal structuring and execution, as well as credit and market risk analysis. -
Jean-Pierre BoisselChief Scientific Officer
Professor of clinical pharmacology at Claude Bernard Lyon 1 University since 1984 and author of more than 300 publications in peer-reviewed journals, Jean-Pierre is one of the founding fathers of systems biology.
At the forefront of innovation in biomedical sciences throughout his career, he co-founded in 1988 the first CRO globally to set up a computer-based on-site system to collect and control clinic trials data.
Previous Investors
-
Founders, family & friendsUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.